Tectonic Advances Dual Pipeline for Rare Diseases on Strong Financials

WATERTOWN, MA – February 26, 2026 – Tectonic Therapeutic (NASDAQ: TECX) today underscored a period of significant clinical momentum, announcing its 2025 year-end financials alongside major advancements for two distinct drug candidates targeting severe diseases with no approved treatments. The clinical-stage biotechnology company is moving forward on two fronts, with promising developments for its pulmonary hypertension therapy, TX45, and the initiation of trials for TX2100, a novel candidate for the rare genetic disorder Hereditary Hemorrhagic Telangiectasia (HHT).

The updates, which include positive clinical data, the launch of two new trials, and the appointment of a heavyweight industry veteran as its new board chair, paint a picture of a company aggressively executing its strategy. Bolstered by a cash reserve of $253.8 million, Tectonic projects a financial runway extending into the fourth quarter of 2028, providing a stable foundation to pursue its ambitious goals.

“Over the last 12 months, we have made significant progress expanding our clinical pipeline,” said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic. “This marks an important milestone for Tectonic which now has two programs in clinical development to address patient populations with high unmet need and no approved therapy.”

A Two-Front Clinical Advance

Tectonic’s lead asset, TX45, is making notable headway in the complex field of pulmonary hypertension (PH). The company previously announced positive topline results from its Phase 1b trial in patients with Group 2 PH due to heart failure with reduced ejection fraction (PH-HFrEF). The data was highly encouraging, showing that a single dose of TX45 was not only well tolerated but also produced significant hemodynamic improvements. Specifically, the trial demonstrated a 29.2% reduction in pulmonary capillary wedge pressure (PCWP)—a key measure of pressure in the heart—and a 17.3% improvement in cardiac output. Critically, for a subpopulation with more severe disease, TX45 also demonstrated reductions in pulmonary vascular resistance (PVR).

Building on this success, Tectonic is expanding the investigation of TX45. The company confirmed that its APEX Phase 2 trial in patients with PH due to heart failure with preserved ejection fraction (PH-HFpEF) is ongoing, with topline results anticipated later in 2026. This form of PH, which affects an estimated 1.4 million people in the U.S., currently has no approved medications, representing a vast unmet medical need.

Furthermore, in February 2026, Tectonic broadened the potential scope of TX45 by initiating a new Phase 2 trial for patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), a severe form of Group 3 PH. This rare condition, characterized by lung scarring and high mortality, has very limited therapeutic options. The new open-label trial will assess the safety and hemodynamic effects of TX45 in these patients, with PVR change being the primary endpoint.

While TX45 advances, Tectonic has officially become a multi-program clinical company. In February 2026, it dosed the first healthy volunteer in a Phase 1a trial for TX2100, a potential first-in-class therapy for Hereditary Hemorrhagic Telangiectasia (HHT). HHT is the second most common inherited bleeding disorder, affecting an estimated 75,000 people in the U.S. alone. Patients suffer from fragile, abnormal blood vessels that cause recurrent, severe bleeding and can lead to life-threatening complications. Despite its prevalence and severity, there are currently no FDA-approved therapies for HHT, with patients relying on supportive care and invasive procedures.

The Science Behind the Pipeline

Tectonic’s strategy is rooted in its proprietary GEODe™ platform, which is designed to overcome historical challenges in drugging a class of proteins known as G-protein coupled receptors (GPCRs). Both TX45 and TX2100 are products of this specialized approach.

TX45 is an engineered Fc-relaxin fusion protein that activates the RXFP1 receptor, the natural target of the hormone relaxin. In the body, relaxin is a powerful vasodilator with anti-fibrotic and anti-inflammatory properties, but its therapeutic use has been hampered by a very short half-life. Tectonic’s fusion protein technology gives TX45 a long-acting profile, potentially unlocking the full therapeutic benefit of the relaxin pathway for cardiovascular and fibrotic diseases like PH.

TX2100, meanwhile, takes a novel approach to HHT. It is an antagonist antibody designed to block the APJ receptor, a GPCR that is upregulated during the pathological blood vessel formation (angiogenesis) characteristic of HHT. By selectively inhibiting this pathway, TX2100 aims to stabilize blood vessels and reduce bleeding, offering a potential disease-modifying treatment rather than merely managing symptoms.

Financial Fortitude and Strategic Leadership

The company's ambitious clinical development is supported by a robust financial position and strengthened leadership. Tectonic ended 2025 with $253.8 million in cash and cash equivalents. While its net loss for the fourth quarter grew to $19.2 million from $12.4 million in the prior year, the increase is primarily fueled by a surge in research and development expenses, which rose to $16.3 million for the quarter. This increased spending directly reflects the costs of advancing both the TX45 and TX2100 programs into and through clinical trials.

The company's confidence is further bolstered by a significant addition to its leadership. Tectonic announced the appointment of François Nader, M.D., MBA, as the incoming Chair of the Board of Directors, effective April 1, 2026. Dr. Nader is a highly respected figure in the biopharmaceutical industry, best known for his transformative tenure as CEO of NPS Pharmaceuticals, which he built into a leading rare disease company before its acquisition by Shire. His extensive board experience includes roles at Moderna, Acceleron Pharma (acquired by Merck), and Alexion Pharmaceuticals (acquired by AstraZeneca), making his appointment a major strategic signal of Tectonic's long-term ambitions.

Charting the Course for 2026 and Beyond

The coming year is poised to be transformative for Tectonic, with several key data readouts on the horizon. The company expects to report topline results from the ongoing APEX Phase 2 trial of TX45 in PH-HFpEF sometime in 2026. This will be a critical test of the drug's efficacy in a large patient population with no treatment options.

In the fourth quarter of 2026, Tectonic anticipates topline safety and pharmacokinetic results from the Phase 1a trial of TX2100. Assuming a positive outcome, the company plans to swiftly initiate a Phase 2 proof-of-concept trial in HHT patients in early 2027, aiming to demonstrate improvements in nosebleeds, anemia, and other key endpoints. With a deep pipeline targeting areas of profound unmet need, a strong balance sheet, and seasoned leadership, Tectonic is positioned for a series of crucial catalysts that could validate its unique scientific platform and bring new hope to patients.